JPMorgan Funds - Thematics - Genetic Therapies

A (acc) USD: LU2050612402

For other available share classes, please check the prospectus.

---

**EXPERTISE**

- Combines a decade of quantitative beta expertise with the specialist insight of our healthcare analysts.

---

**PORTFOLIO**

- Proprietary thematic engine uses natural language processing over vast data sets to identify companies involved in the field of genetic therapies.
- Provides broad, diversified exposure to the genetic therapies theme through both developed and emerging market equities, across the market cap spectrum.

---

**RESULTS**

- Diversified access to all stages of development in a fast-growing industry.

---

**ACTIVE TRIALS FOR GENE THERAPY PRODUCTS**

![Active Trials Graph]


---

**INVEST IN A GROUNDBREAKING HEALTHCARE GROWTH DRIVER**

Genetic therapies seek to cure disease by modifying genetic information. These innovative therapies are seeing an acceleration of scientific breakthroughs, regulatory approvals and commercially viable launches, across a broad range of diseases, attracting increasing investment from cash-rich large pharmaceutical companies.

Genetic Therapies Fund is an early-stage opportunity to invest in this potentially long-term secular theme. The fund invests across the market capitalisation spectrum, providing diversified exposure to both innovative pioneers and established healthcare players.

---

**PROJECTED MARKET GROWTH**

![Projected Market Growth Graph]

Source: J.P. Morgan Asset Management as at 30 September 2019

Opinions, estimates, forecasts, projections and statements of financial market trends are based on market conditions at the date of the publication, constitute our judgment and are subject to change without notice. There can be no guarantee they will be met.

---

**THEMEBOT: CAPTURING THE GENETIC THERAPIES OPPORTUNITY**

Genetic Therapies Fund is powered by ThemeBot, a thematic investment engine built by Quantitative Beta Strategies at J.P. Morgan Asset Management.

ThemeBot screens more than 10,000 stocks globally, using natural language processing to analyse hundreds of millions of data sources and identify companies with the highest exposure to the genetic therapies theme, regardless of size.

The result is a high-relevance, diversified portfolio optimised for liquidity, market capitalisation and valuation. The output is validated and refined by our highly experienced fundamental healthcare analysts.

---

**WHY J.P. MORGAN ASSET MANAGEMENT?**

- A commitment to putting clients’ interests first
- A legacy of innovative investing
- Comprehensive and disciplined portfolio management
- The resources of a truly global organization.
J.P. Morgan Asset Management Quantitative Beta Strategies Team as at 30.06.2019:
- Pioneer in managing alternative beta strategies
- Emphasis on innovation, research and development

Yazann Romahi
Portfolio manager
- 19 years of industry experience,
  16 at J.P. Morgan

Berkan Senen
Portfolio manager
- 7 years of industry experience,
  2 at J.P. Morgan

Aljaz Hussain
Portfolio manager
- 5 years of industry experience,
  3 at J.P. Morgan

INVESTMENT OBJECTIVE
To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.

PERFORMANCE
As the fund inception date is less than a year ago, performance is not currently available.

RISK PROFILE
The Sub-Fund is subject to Investment risks and Other associated risks from the techniques and securities it uses to seek to achieve its objective.

The table on the right explains how these risks relate to each other and the Outcomes to the Shareholder that could affect an investment in the Sub-Fund. Investors should also read Risk Descriptions for a full description of each risk.

<table>
<thead>
<tr>
<th>Investment risks</th>
<th>Risks from the Sub-Fund's techniques and securities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Techniques</td>
<td>Securities</td>
</tr>
<tr>
<td>Concentration</td>
<td>Emerging Markets</td>
</tr>
<tr>
<td>Hedging</td>
<td>Equities</td>
</tr>
<tr>
<td>Thematic</td>
<td></td>
</tr>
</tbody>
</table>

Other associated risks
Further risks the Sub-Fund is exposed to from its use of the techniques, strategies and securities above

<table>
<thead>
<tr>
<th>Currency</th>
<th>Liquidity</th>
<th>Market</th>
</tr>
</thead>
</table>

Outcomes to the Shareholder
Potential impact of the risks above

- Loss Shareholders could lose some or all of their money.
- Volatility Shares of the Sub-Fund will fluctuate in value.
- Failure to meet the Sub-Fund's objective.

FOR PROFESSIONAL CLIENTS / QUALIFIED INVESTORS ONLY – NOT FOR RETAIL USE OR DISTRIBUTION.

The term ‘Fund’ used throughout this document refers to the relevant ‘Sub-Fund’, which is a legal term used in the Prospectus. This is a marketing communication and as such the views contained herein do not form part of an offer, nor are they to be taken as advice or a recommendation, to buy or sell any investment or interest thereto. Reliance upon information in this material is at the sole discretion of the reader. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are, unless otherwise stated, J.P. Morgan Asset Management’s own at the date of this document. They are considered to be reliable at the time of writing, may not necessarily be all inclusive and are not guaranteed as to accuracy. They may be subject to change without reference or notification to you. It should be noted that the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying overseas investments. Past performance and yield are not a reliable indicator of current and future results. There is no guarantee that any forecast made will come to pass. Furthermore, whilst it is the intention to achieve the investment objective of the investment products, there can be no assurance that those objectives will be met. J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy www.jpmorgan.com/emea-privacy-policy. As the product may not be authorised or its offering may be restricted in your jurisdiction, it is the responsibility of every reader to satisfy himself as to the full observance of the laws and regulations of the relevant jurisdiction. Prior to any application investors are advised to take all necessary legal, regulatory and tax advice on the consequences of an investment in the products. Shares or other interests may not be offered to, or purchased, directly or indirectly by US persons. All transactions should be based on the latest available Prospectus, the Key Investor Information Document (KIID) and any applicable local offering document. These documents together with the annual report, semi-annual report and the articles of incorporation for the Luxembourg domiciled products are available free of charge upon request from JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningenberg, Grand Duchy of Luxembourg, your financial adviser or your J.P. Morgan Asset Management regional contact. In Switzerland, JPMorgan Asset Management (Switzerland) LLC, Dreikönigstrasse 32, 8002 Zurich, acts as Swiss representative of the funds and J.P. Morgan (Suisse) SA, 8 Rue de la Confédération, 1204 Geneva, as paying agent of the funds. JPMorgan Asset Management (Switzerland) LLC herewith informs investors that with respect to its distribution activities in and from Switzerland it receives commissions pursuant to Art. 34 para. 2 of the Swiss Collective Investment Schemes Ordinance dated 22 November 2006. These commissions are paid out of the management fee as defined in the fund documentation. Further information regarding these commissions, including their calculation method, may be obtained upon written request from JPMorgan Asset Management (Switzerland) LLC. This communication is issued in Europe (excluding UK) by JPMorgan Asset Management (Europe) S.à r.l., 6 route de Trèves, L-2633 Senningenberg, Grand Duchy of Luxembourg, R.C.S. Luxembourg B27900, corporate capital EUR 10.000.000. This communication is issued in the UK by JPMorgan Asset Management (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. Registered in England No. 01161446. Registered address: 25 Bank Street, Canary Wharf, London E14 5JP.